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Astrocytes are crucial for postnatal development of neuronal networks, axon myelination and neu-
rovascular structures. Defects in astrocyte generation or maturation are associated with severe neu-
rological developmental disorders. Glutaric acidemia type I (GAI), an inherited neurometabolic
disorder characterized by accumulation of glutaric (GA) and 3-hydroxyglutaric acids, shows a
paradigmatic postnatal neuropathology characterized by massive degeneration of neurons in the
striatum. While the disorder is caused by genetic mutations on glutaryl-CoA dehydrogenase, the
neurological defects usually start months after birth. Pathogenesis of GAI has remained largely
unknown, and specifically, it is unclear how accumulation of GAI metabolites may result in neu-
rodegeneration. Recent evidence supports a GAI model involving primary defective astrocyte matu-
ration leading to a co-morbid spectrum of neurologic symptoms similar to those of patients.
Astrocytes are vulnerable to GAI metabolites, but instead of dying, they follow long-lasting pheno-
typic changes leading to striatal neuron degeneration as well as defective myelination and blood
brain barrier maturation. Here, we summarized recent findings on the pathogenic role of GA-
damaged astrocytes in GAI and discuss if astrocyte dysfunction may be a target of therapeutic
interventions.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Astrocytes represent about 20–50% of the brain volume in
humans and this value may increase with astrocytic swelling or
sustained proliferation in response to metabolic or energetic dam-
age [1–3]. Since astrocytes provide structural and metabolic sup-
port to neurons, synapsis and other glial cells, their functional
specialization and complexity augment as neurons progressively
organize into mature functional circuits and undergo myelination
during early post-natal development [2,4,5]. In addition, astrocytes
are the main source of endogenous glutamine and lactate, which
are the major metabolic precursors for fueling neurons and neuro-
transmitter biosynthesis [6]. In doing so, they provide substrates
for neuronal intermediary metabolism, antioxidant balance, neuro-
transmitter synthesis as well as myelination [5,7,8]. Astrocytes also
critically participate in sustaining blood brain barrier (BBB) func-
tion and formation of gap junction-coupled functional networks
[9,10]. Such intercellular coupling seems to be essential for regula-tion of extracellular ionic composition and for providing nutrients
to neurons and oligodendrocytes (OLs) [2,4].
An important concept for understanding postnatal brain devel-
opment is that it largely depends on the ability of astrocytes to
reach fully differentiated phenotypes, a condition requiring normal
functioning of most organelles as well as intact capacity for gene
expression and protein synthesis [4,5,11]. The poly-functional
properties of astrocytes seem to be robust and likely redundant,
assuring the normal organization and functioning of the CNS dur-
ing decades of life. However, astrocyte damage during postnatal
development due to trauma, ischemia and genetic or metabolic
disorders can dramatically affect normal maturation, thereby
increasing the probability of impaired brain development [5,12].
Another concept to understand brain damage relates to the ability
of astrocytes to undergo reactive phenotypes [4,11,13]. Astrocyto-
sis, defined as increased cell number and/or hypertrophic cell bod-
ies overexpressing glial fibrillary acidic protein (GFAP) and
inflammatory markers, is a prototypical damage response in adult
astrocytes [2–4]. Available evidence indicates that reactive astro-
cytic phenotypes occurring during early postnatal life could differ
from those of the adult brain. Early postnatal astrocytes react to
damage by increasing proliferation, un-differentiation, loss of
Fig. 1. Cytotoxic effects of glutaric acid (GA) on astrocytes. Astrocytic accumulation
of GA and 3OHGA elicits early mitochondrial dysfunction associated with oxidative
stress and activation of mitogenic cascades with consequent increased cell
proliferation and phenotypic features of undifferentiated astrocytes expressing
low GFAP levels [14,32]. Inflammatory cascades dependent on increased S100b
expression are also activated, possibly causing the perpetuation of the undifferen-
tiated phenotype. Abbreviations: GA and 3HGA, glutaric and 3-hydroxyglutaric
acids; GCDH, glutarylCoA dehydrogenase; GFAP, glial acidic fibrillary protein; Lys,
lysine; pERK, phosphorylated extracellular regulated kinases; TCA, tricarboxylic
cycle acids; Trp, tryptophan.
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formation of a cellular or fibrotic scar [5,14,15]. This damage
response has the potential to profoundly influence neuronal and
synaptic activity, and could lead to a non-permissive environment
for neuron survival, synaptic activity, axonal growth and migration
of OL precursors [5,9,15]. Appropriate astrocyte function and dif-
ferentiation is thus required to sustain postnatal brain develop-
ment, including formation of neuronal circuits and associated
neurovascular and myelinated structures.
There are several pathological conditions where primary neona-
tal damage to astrocytes promotes secondary neuronal death and/
or leukodystrophy. The best recognized examples of leukodystro-
phies caused by primary astrocytopathies are Alexander disease,
Vanishing White Matter (VWM) disease or post-ischemic perivas-
cular leukomalacia, conditions where an aberration in neurological
development appears abruptly during postnatal life or as a delay in
development [12,16–17]. Astrocytes also appear to be damaged, in
particular, as a result of inborn errors of metabolism where genetic
mutations lead to profound alteration of amino acid catabolic path-
ways resulting in brain toxicity [6,12,17,18].
Since the first description by Goodman et al. [19], more than
500 reports have been published on Glutaric acidemia-I (GAI), a
devastating neurometabolic disorder that affects around
1:30,000–100,000 infants. GAI is caused by recessive mutations
of glutaryl-CoA dehydrogenase (GCDH), a mitochondrial flavin-ade
nine-dinucleotide-requiring enzyme that catalyzes glutaryl-CoA
dehydrogenation in the catabolic pathway of the amino acids,
lysine, hydroxylysine and tryptophan [20–22]. GCDH deficiency
results in accumulation of neurotoxic concentrations of glutaric
(GA) and 3-hydroxyglutaric (3OHGA) acids, both five-carbon dicar-
boxylic acids [20–23]. At birth, most GAI patients are devoid of
symptoms [20–23], but may show progressive macrocephaly due
to increased cerebral mass [21–26]. If the disease is not diagnosed
early in postnatal life and treated mainly with a diet low in the
amino acids fueling GA production, GAI usually manifests clinically
as acute encephalopathic crisis precipitated by catabolic conditions
between 3 and 18 months [19,20,23]. Following clinical presenta-
tion, GAI remains as a chronic neurological disease characterized
by progressive striatal and cortical neuronal degeneration as well
as white matter abnormalities, and results in dystonia or dyskine-
sia as permanent neurologic sequel [18–22,27].
Several mechanisms have been proposed to explain pathogene-
sis and degeneration of striatal and cortical neurons in GAI.
Because high concentrations of GA can potentially interact with
glutamate receptors and transporters, excitotoxicity has been
among the leading hypotheses for GAI pathogenesis [21,27]. Oxida-
tive stress, energetic failure, metabolic acidosis and deficit in car-
nitine have also been proposed as alternative or aggravating
neurotoxic mechanisms [28–31]. However none of these mecha-
nisms is sufficient to explain the clinical and pathological hall-
marks of GAI as a neurometabolic disorder.
An alternative hypothesis proposes that neurodegeneration in
GAI is caused by non-cell autonomous mechanisms in which inter-
actions between glial or neuronal cells contribute to neurodegen-
erative processes [14,32–35]. In particular, this hypothesis is
based on the observation that increased GA levels in the CNS trig-
ger long lasting astrocyte dysfunction that in turn, subsequently
elicits secondary striatal neuronal loss [32], delayed myelination
[34], altered BBB permeability and neurovascular unit failure
[35]. Taken together, this new proposed mechanism for GAI patho-
genesis could lead to new preventive and/or therapeutic
approaches for patients.
Extensive reviews have recently been published on GAI [23,36–
39]. Here, we will review the cumulative evidence supporting the
astrocytic hypothesis for GAI, as a new model for neurodegenera-
tion dependent on a primary astrocyte dysfunction.2. Astrocytes as targets for glutaric acid and related metabolites
Because of the key role played by astrocytes in neuronal inter-
mediary energetic metabolism as well as in synaptic homeostasis,
they represent a particularly vulnerable cell type in GAI [2,7,39].
Astrocytes can actively uptake GA and related metabolites [40] as
they have the ability to transport glutamate and dicarboxylic acids
into the intracellular compartment. Astrocytes also express
sodium-dependent dicarboxylate cotransporter-3 that could fur-
ther uptake extracellular GA and 3OHGA [41,42]. In addition, we
have recently provided evidence that astrocytes express low levels
of GCDH, therefore they could accumulate GA and 3HGA if the
enzyme is defective [33].
We have also shown that high concentrations of GA in astro-
cytes cause severe mitochondrial dysfunction including altered
downstream signal transduction pathways. These alterations can
impact heavily on cell phenotype and proliferative potential
[14,32,33], as summarized in Fig. 1. Other studies have also
reported deleterious effects of GAI metabolites on astrocytes, all
having significant neurotoxic potential. These effects include
induction of astrocyte swelling and loss of function of glutamine
synthase [43] as well as defective metabolic support for neurons
[42]. Interestingly, accumulation of GAI metabolites in astrocytes
does not result in direct lethal toxicity to astrocytes as could be
expected [14]. Instead, astrocytes respond with functional and
phenotypic changes as a way to adapt to increased concentrations
of GAI metabolites. However, such metabolic adaptation is
achieved at the expense of increased astrocyte proliferation associ-
ated with an immature phenotype. Ultimately these astrocytes will
fail to support neuronal survival and synaptic homeostasis and
thereby trigger neurodegeneration [32–34]. This mechanism
would explain the delayed clinical onset of GAI, months or years
after birth, coincident with developmental maturation of excita-
tory synapsis and myelination in the basal ganglia.
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Previously, we developed a method to reproduce the GAI
encephalopathic crisis by injecting a single, non-lethal bolus of
GA (5 mM) into the cisterna magna of newborn rat pups [14].
Injected pups develop immediate convulsions for 1–2 min fol-
lowed by complete recovery and subsequent normal development.
Histopathological analysis of GA-treated pup brains showed S100-
b positive astrocytosis in the striatum and increased proliferation
that was observed as early as 24 h after GA administration and
which lasted up to 45 days [14,32]. The fact that a single intracere-
broventricular (icv) injection of GA elicited a glial response lasting
several weeks was surprising and suggested the triggering of an
autotoxic loop induced by GA. Moreover, the same phenotype
was evident in cultured neonatal astrocytes treated with GA, i.e.,
cells displayed poorly differentiated phenotypes with high S100b
and low GFAP expression [14,32]. In culture, GAI metabolites stim-
ulated the proliferation rate of astrocytes but not that of other glial
cells such as OLs [14,32]. Increased proliferation appears to be
dependent on mitochondrial dysfunction and MEK/ERK pathway
activation and is abrogated by pretreatment with MAPK inhibitors
or antioxidants [14].
In this context, we speculate that the macrocephaly frequently
observed preceding overt neurological deficits in GAI patients [19–
21,25], may be due to the increased volume of astrocytes caused by
accumulation of GAI metabolites. This hypothesis implies the
occurrence of a long and silent period where astrocytes are dys-
functional, in an attempt to adapt to GA overload. However, astro-
cyte adaptation can be surpassed in the case of systemic infection
or other catabolic state thus leading to the typical encephalopathic
crisis and subsequent neurological deficits.
Macrocephaly is not a symptom specific for GAI because it can
also be associated with other metabolic disorders including 2-
hydroxyglutaric aciduria (2-HGA) [17,20,21]. Accumulated
metabolites (2-hydroxyglutarates, 2-HG) in HGA are associated
with a well-established proliferative effect. In addition, 2-HG, are
accumulated in low-grade gliomas displaying isocitrate dehydro-
genase mutations that also can result in macrocephaly [44,45].
Thus, GAI metabolites as well as those of 2-HGA might accumu-
late in astrocytes, promoting mitochondrial dysfunction and
mitogenic pathways and also leading to progressive macro-
encephaly.
2.2. Astrocyte damage and progressive striatal degeneration
While GAI patients usually exhibit massive striatal degenera-
tion and permanent motor damage sequels [21–24], such dramatic
motor phenotypes have not been described in GAI animal models
in basal conditions [46,47]. Moreover, whereas very high dietary
protein or lysine concentrations caused significant neuronal death
and quick lethality in GCdh / mice [48,49], these animals fed
with lysine diets that quintuplicate normal values did not kill stri-
atal neurons but cause oxidative stress [31]. In our model of single
icv administration of GA to rat pups, there is moderate striatal
degeneration with no significant motor symptoms [14,32].
Remarkably, GAI induced neuronal death was delayed by 21 days
[32], suggesting neurons are not directly vulnerable to GA but
instead to the cellular reaction of astrocytes to GA, including
S100b astrocytosis. Moreover, striatal neurons maintained in cul-
ture were unresponsive to GA even at millimolar concentrations,
but were killed by conditioned media of astrocytes treated with
GA. Consistent with this, other studies have shown that high con-
centrations of GA and 3HGA altered ammonia metabolism in sur-
rounding neurons and OLs [42], which might lead to altered
astrocyte potassium buffering and calcium signaling propitiating
increased neuronal excitability and seizures [50]. Therefore, fol-lowing a catabolic event or at maximal concentrations of GA or
3HGA astrocyte homeostatic capacities become ineffective thereby
eliciting a neurodegenerative cascade through a non-cell autono-
mous mechanism in which neuronal loss is mediated by astrocytes
[32].
2.3. Dysfunctional astrocytes underlie myelination failure
White matter defects are a common finding in GAI patients and
represent a condition contributing to neurologic deficiencies and
delay in development [19–24]. Recently, we explored whether dys-
functional astrocytes in GAI also contributed to defects in postnatal
myelination. We found that perinatal icv administration of GA to
newborn rats provoked serious damage in postnatal myelination
that was typically delayed by 2 weeks after the treatment. Such
myelination failure was characterized by decreased expression of
myelin associated glycoprotein and myelin binding protein in the
striatal bundles [35]. Compared with controls, myelination in GA-
animals was weaker and less developed, suggesting a direct corre-
lation with delayed OL differentiation. In fact, OL appearance
became progressively rounded and lacking processes with MAG
staining restricted to the cell body indicating altered protein trans-
port and delivery to cell processes close to axons. Transmission
electron microscopy showed that striatal OLs from rats injected
with GA had endoplasmic reticulum (ER) with significant swollen
vesicles indicating significant ER stress. Abnormal myelin sheaths
and thinner axons were also consistently found in GAI injected ani-
mals [35], all resembling the progressive myelin alterations
reported in GAI patients [23,51]. Interestingly, GAI induced myeli-
nation failure was restricted to the basal ganglia, the most vulner-
able brain area in GAI patients [19,20,23].
Because GA did not induce acute damage to OLs or preOLs in
neonatal pups [34] as well as in cultured preOLs but was closely
associated with proliferation of undifferentiated astrocytes, we
postulated that delayed OL pathology was secondary to disrupted
astrocyte-OL communication. In agreement, astrocytes activated
with GA in culture produced soluble factors that seemed not per-
missive for OL survival and differentiation. Multiple trophic factors
produced by astrocytes are required for survival of developing OLs
[5,7,8], thus even small changes in astrocytic function may be
detrimental to OL survival and lead to defective myelination
[5,7,8,17]. Thus, exacerbated astrocyte proliferation and immature
phenotypes elicited by GAI metabolites may result in defective sig-
naling by astrocyte to support OL maturation.
VWM and Alexander disease represent other neonatal disorders
where primary astrocyte dysfunction leads to paradigmatic
leukodystrophies [16,17,52]. VWM is caused by mutations in genes
of the family of eukaryotic initiation factor 2B, eIF2B. Like GAI,
VWM disease predominantly manifests in early childhood with a
rapid neurologic decline triggered by stress-related events [16].
In VWM, astrocytes show increased proliferation, immature phe-
notypes, abnormal composition of intermediate filament networks
and metabolic stress [50]. Loss of white matter might be due to a
lack of mature astrocytes to support myelination and/or excessive
astrocyte proliferation at the expense of OL common progenitors.
Similarly, several mutations in GFAP underlying Alexander disease
lead to striking astrocyte pathology that correlated with myelin
alterations [17], further suggesting that dysfunctional astrocytes
in different genetic or metabolic disorders may lead to similar
lesions of the white matter.
2.4. The astrocyte-blood brain barrier connection
Cajal first reported the close association of astrocytes with brain
capillaries, describing the polarized astrocytic specialization
known as ‘‘end feet” [2]. Subsequent studies have shown that
Fig. 2. Time course and pathological events induced by cytotoxic levels of glutaric
acid. (A) The cartoon depicts the sequence of events following a single adminis-
tration of GA into the cysterna magna of newborn rats. The initial astrocyte reaction
characterized by proliferation and S100b expression [14,32] is followed by striatal
neuronal death starting days later. Delayed myelination [34] and BBB maturation
[35] lasting for weeks is also observed. (B) Schematic illustration showing the
putative effects of astrocyte dysfunction elicited by GA [14,31–35]. Loss of
homeostatic astrocyte control and mitochondrial dysfunction may cause glutamate
release increasing the risk of excitotoxicity and oxidative stress [2–4,11,12] to
neurons. A decreased energetic and metabolic support [4–6,11,12,39] as well as
ammonia toxicity may also significantly affect neuronal survival [4–6,11,39,43,48].
Excitotoxicity together with oxidative stress and decreased secretion of pro-
myelinating signals may impede oligodendrocyte (OL) maturation and favor
proliferation of OL precursors (preOL) [4,5,39]. Increased S100-b-dependent
inflammatory cascades and loss of homeostasis may alter the neurovascular unit
(NVU) causing decreased number of pericytes associated to blood vessels (green) as
well as diminished expression of laminin in the basal lamina (orange) and of
aquaporin 4 (AQP4) in astrocyte endfeet (yellow) [35].
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and stabilization [9,10]. Thus, based on the fact that astrocytes fail
to undergo appropriate differentiation after exposition to toxic
concentrations of GA, we analyzed the status of the BBB in rat pups
receiving an icv bolus of GA. Similar to vascular dysfunctions
reported in GAI patients [21–24] as well as BBB breakdown
described during acute encephalopathic crises in GCDH-deficient
mice [48,49], GA-injected animals exhibit an increased BBB perme-
ability to low molecular weight compounds such as Evans Blue
(EB). Such increased permeability of the BBB can be observed up
to 30 days following GA administration compared with disappear-
ance of passive leakage in control animals. Interestingly, EB
extravasation through the BBB was internalized in striatal neurons
but not in astrocytes or microglial cells. This suggests concurrent
membrane anomalies in damaged striatal neurons allowing pas-
sive entrance of the dye [35].
Pups treated with GA also exhibit other striking defects of the
neurovascular unit in the striatum. Disturbances include a reduc-
tion of the astrocytic protein aquaporin 4 (AQP4) typically enriched
in end feet processes [35,53], decreased number of pericytes and
altered laminin expression in the basal lamina [54]. Such defective
development of the neurovascular unit observed after a single
bolus of GA is suggestive of altered astrocyte differentiation and
polarization that may impair proper BBB development and func-
tion [53,54], as shown in GAI patients [22,24]. Evidence indicates
that endothelial cells and pericytes may also be affected long peri-
ods after GA treatments. Results show defective laminin patterns
in endothelial cells and nearly the absence of pericytes in the neu-
rovascular unit which in turn also affects astrocyte end feet polar-
ization [54]. Therefore, striatal astrocytes seem to be particularly
vulnerable to GA, which prevent normal astrocyte differentiation
and polarization at the level of the neurovascular unit, and results
in both structural and functional abnormalities of the BBB and its
permeability.
3. Conclusions and perspectives
Nowadays, GAI is mostly a preventable disease that can be diag-
nosed through perinatal amino acid screening and treated with a
correct life-long diet and nutritional supplements. In despite of
this, many GAI patients in either symptomatic or asymptomatic
phase of the disease would also benefit by neuroprotective drugs
preventing a potential neurological deterioration in case of infec-
tion or catabolic metabolism. Current evidence indicating a patho-
genic role for astrocytes in GAI represents a major conceptual and
therapeutic challenge. Thus, new pharmacological interventions
could be directed to protect astrocytes. Unfortunately, there is a
lack of specific astrocyte-targeted drugs that could prevent the
transition to the deleterious and partially differentiated pheno-
types in response to GA. Such ideal astrocytic protective drugs
would greatly benefit symptomatic GAI patients, minimizing the
cascade of events leading to neuronal damage, myelination failure
and neurovascular defects. Normalization of astrocyte functions in
GAI would also permit the repair and rehabilitation process, allow-
ing for subsequent development of the CNS.
The pathogenic role of astrocytes in GAI also represents a
paradigmatic example of the key contribution of glial cells in post-
natal brain development. Patients with GAI present a remarkable
overlap of neurological deficits and a characteristic temporal
course that could hardly be explained by a direct cytotoxic effect
of GA on neurons and synapsis. Rather, what we have learnt from
animal models indicates that GAI represents a primary astrogliopa-
thy affecting neuronal and synaptic metabolism, coincident with
major disruption of the neurovascular and white matter establish-
ment. Fig. 2 summarizes the hypothetical temporal course of GAIpathology, as mediated by astrocyte dysfunction. First, in the
pre-symptomatic phase of the disease astrocytes might compen-
sate increased GA levels by proliferating and increasing their total
volume, a condition that could underlie macrocephaly. At later
times of neurodevelopment, the inability of GA-damaged astro-
cytes to undergo appropriate differentiation no longer supports
the increasing demands needed for development of synaptic net-
works, myelination and the BBB, thereby leading to neurodegener-
ation. Finally, after the disease has been controlled by diet and
supplements, the persistence of dysfunctional astrocytes may
impede repair or rehabilitation mechanisms, perpetuating the neu-
rologic sequel and development delay. The hypothesis based on the
pathogenic role of astrocytes in GAI might be important to under-
stand other genetic or metabolic disorders or pathological condi-
tions that affect postnatal neurodevelopment.
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